Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has announced Biosyntia, a biotechnology company focused on synthetic biology and metabolic engineering, has adopted the Pico-Mine®platform within its workflows. The platform was chosen by Biosyntia to harness its ultra-high-throughput, picodroplet-based screening capabilities, to accelerate development of novel industrially-relevant cell factories and advance bio-based production of nutritional ingredients...
Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announce that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Company’s growth. Doubling overall capacity, the laboratories enable the team’s accelerated expansion, and the development of new, innovative products...
First in Sphere Fluidics’ new range of 3D cell culture kits in partnership with ClexBio. Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, announce the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit...
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leading supplier of intelligent laboratory automation solutions, have announced the optimization of the Cyto-Mine® Single Cell Analysis System through integration with PAA’s automated plate handler, S-LAB™. The addition of S-LAB to the Cyto-Mine provides researchers with a further streamlined solution for single cell analysis...
The Cyto-Cellect Human IgGK Detection Kit has been developed to provide Cyto-Mine users with an easy-to-use, standardized assay format for the detection of secreted human antibodies in picodroplets. The sensitive FRET-based assay rapidly detects the presence of human IgG with kappa light chain after secretion from encapsulated cells, to characterize and measure antibody production....
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, has introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis....
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, has announced that it has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the Company’s accelerated expansion and accommodate its plans for further growth....
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announce that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine ®Single Cell Analysis System, expansion of the UK facility and enable....
Investment received from Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket. Funding will be used to accelerate growth in operations and sales across the UK and USA. Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that is has closed a $2 million (circa£1.5 million) investment round...
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leader in the industry for the design and manufacture of automated laboratory equipment, will collaborate to offer automated micro-plate handling capabilities for single cell analysis. PAA's S-LAB™ plate handler will be integrated with Sphere Fluidics’ Cyto-Mine® Single Cell Analysis System...
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced Cyto-Mine® Studio Software Suite, an updated software for its innovative Cyto-Mine Single Cell Analysis System. The software works alongside industry-standard robotic platforms and corporate databases to improve antibody discovery and cell line development workflows...
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, has announced that Tris Vaughan, PhD FRSB has joined its scientific advisory board (SAB). Dr Vaughan’s appointment will further strengthen the company’s understanding of biopharmaceutical discovery and cell line development and help translate its technology to an industrial context...
€1.6 million grant will support ‘precise docking of very large DNA cargoes in genomes’ project
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, and Geneva Biotech, an EMBL spin-out developing world-class viral and non-viral DNA delivery systems, have received a €1.6 million grant from Eurostars....
Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, has announced Biosyntia, a biotechnology company focused on synthetic biology and metabolic engineering, has adopted the Pico-Mine®platform within its workflows. The platform was chosen by Biosyntia to harness its ultra-high-throughput, picodroplet-based screening capabilities, to accelerate development of novel industrially-relevant cell factories and advance bio-based production of nutritional ingredients...
Sphere Fluidics, a company developing single cell analysis systems underpinned by its patented picodroplet technology, announce that it has opened a new state-of-the-art facility in Granta Park, Cambridgeshire, UK, to support the Company’s growth. Doubling overall capacity, the laboratories enable the team’s accelerated expansion, and the development of new, innovative products...
First in Sphere Fluidics’ new range of 3D cell culture kits in partnership with ClexBio. Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and ClexBio, a pioneer in solutions for tissue engineering and single-cell techniques, announce the launch of the biocompatible CYTRIX Microfluidic Hydrogel Kit...
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leading supplier of intelligent laboratory automation solutions, have announced the optimization of the Cyto-Mine® Single Cell Analysis System through integration with PAA’s automated plate handler, S-LAB™. The addition of S-LAB to the Cyto-Mine provides researchers with a further streamlined solution for single cell analysis...
The Cyto-Cellect Human IgGK Detection Kit has been developed to provide Cyto-Mine users with an easy-to-use, standardized assay format for the detection of secreted human antibodies in picodroplets. The sensitive FRET-based assay rapidly detects the presence of human IgG with kappa light chain after secretion from encapsulated cells, to characterize and measure antibody production....
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, has introduced an updated version of its Cyto-Mine® Studio Software Suite, a collection of software controlling operation of its Cyto-Mine Single Cell Analysis System, data acquisition and follow-up analysis....
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, has announced that it has opened a new office space at Granta Park in Cambridgeshire, UK. The new facilities support the Company’s accelerated expansion and accommodate its plans for further growth....
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announce that it has closed an additional tranche of investment of $2.9 million (£2.2 million), securing a total of $4.8 million (£3.7 million) in investment. The funding will be used as working capital for the Company’s Cyto-Mine ®Single Cell Analysis System, expansion of the UK facility and enable....
Investment received from Greenwood Way Capital, Oxford Technology and Innovations EIS Fund and 24Haymarket. 
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leader in the industry for the design and manufacture of automated laboratory equipment, will collaborate to offer automated micro-plate handling capabilities for single cell analysis. PAA's S-LAB™ plate handler will be integrated with Sphere Fluidics’ Cyto-Mine
Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced Cyto-Mine® Studio Software Suite, an updated software for its innovative Cyto-Mine 
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, has 
Sphere Fluidics, a company providing single cell analysis systems underpinned by its patented picodroplet technology, and Geneva Biotech, an EMBL spin-out developing world-class viral and non-viral DNA delivery systems, have received a €1.6 million grant from Eurostars....